Browse our 1,000+ Publications​

Latest Publications

Outpatient venetoclax initiation following obinutuzumab debulking in patients with high or medium tumor burden at baseline

Sharman J, et al.
Leukemia & Lymphoma
November 2026
Authors and Affiliates
Jeff P Sharman 1, David Andorsky 2, Jason Melear 3, Sudhir Manda 4, Bertrand Anz 3rd 5, Habte Yimer 6, John M Burke 7, Suzanne Fanning 8, Jay Courtright 9, Suman Kambhampati 10, Zhuangzhuang Liu 11, Brenda Chyla 11, Wendy Sinai 11, Ian Flinn 12 1Willamette Valley Cancer Institute and Sarah Cannon Research Institute, Eugene, OR, USA. 2Rocky Mountain Cancer Centers and US Oncology Research, Boulder, CO, USA. 3Texas Oncology-Austin Midtown and US Oncology Research, Austin, TX, USA. 4Tucson Oncology, TMC Health Cancer Center, Tucson, AZ, USA. 5Tennessee Oncology Chattanooga, Chattanooga, TN, USA. 6Texas Oncology-Tyler and US Oncology Research, Tyler, TX, USA. 7Rocky Mountain Cancer Centers Aurora and US Oncology Research, Aurora, CO, USA. 8Prisma Health, Greenville, SC, USA. 9Texas Oncology-Dallas, Dallas, TX, USA. 10Sarah Cannon Cancer Institute, HCA Midwest Health, Research Medical Center, Kansas City, MO, USA. 11AbbVie Inc, North Chicago, IL, USA. 12OneOncology and Tennessee Oncology Center for Blood Cancer, Nashville, TN, USA.

A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma

Crombie J, et al.
Blood
October 2026
Authors and Affiliates
Jennifer L. Crombie, MD1, Robert Redd, BA2, Clare Phiney, BA1, Megan Forsyth, BA1, Juniper Mai, BA1, Sandra Re, RN1, Ann LaCasce MD1, Oreofe Odejide MD1, Erin Parry, MD, PhD1, David Qualls, MD1, Christine Ryan, MD1, Reid W. Merryman, MD1, David C. Fisher, MD1, Austin I. Kim, MD1, Caron Jacobson MD1, Eric Jacobsen MD1, Jennifer R. Brown, MD, PhD1, Inhye E. Ahn MD1, Matthew S. Davids, MD, MMSc,1 Gottfried von Keudell, MD3, Alvaro Alencar, MD4, Michele Stanchina, DO, MS4, Russ Kuker, MD5, Craig Moskowitz, MD4, Philippe Armand, MD, PhD1, Juan Pablo Alderuccio, MD4 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA 3Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA 4Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, Miami, FL, USA 5Department of Radiology, Division of Nuclear Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA

First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival

Niemann C, et al.
Leukemia
October 2026
Authors and Affiliates
Carsten U. Niemann 1✉, Talha Munir2, Carolyn Owen3, George Follows4, José-Ángel Hernández-Rivas 5, Ohad Benjamini6, Ann Janssens7, Mark-David Levin 8, Tadeusz Robak 9, Martin Simkovic10, Sergey Voloshin11, Vladimir Vorobyev 12, Loic Ysebaert13, Natasha Schuier14, Kurt Baeten15, Nguyet Tran16, Bennett Levitan16, Claire Kavanagh17 and Arnon P. Kater 18 1Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 2St James’s University Hospital, Leeds, UK. 3Tom Baker Cancer Centre, Calgary, AB, Canada. 4Addenbrookes Hospital, Cambridge, UK. 5Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain. 6Sheba Medical Center, Ramat Gan, Israel. 7Universitaire Ziekenhuizen Leuven, Leuven, Belgium. 8Albert Schweitzer Hospital, Dordrecht, Netherlands. 9Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland. 104th Department of Internal Medicine—Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czechia. 11Russian Scientific and Research Institute of Hematology and Transfusiology, St, Petersburg, Russia. 12S.P. Botkin Moscow City Clinical Hospital, Moscow, Russia. 13Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France. 14Johnson & Johnson, Zug, Switzerland. 15Johnson & Johnson, Beerse, Belgium. 16Johnson & Johnson, Titusville, NJ, USA. 17Johnson & Johnson, Dublin, Ireland. 18Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, HOVON foundation, Amsterdam, Netherlands.

Dasatinib-based induction and blinatumomab + TKI consolidation/maintenance forBCR::ABL1+ ALL: BLISSPhALL Study Results

Geyer M, et al.
Blood Neoplasia
September 2026
Authors and Affiliates
Mark Geyer(Medicine,Memorial Sloan Kettering Cancer Center,United States) John Mascarenhas(Hematology Oncology,Icahn School of Medicine at Mount Sinai,United States) Michal Bar- Natan(,Weill Cornell Medical College and New York-Presbyterian Hospital,United States) Marissa Smith(,Memorial Sloan Kettering Cancer Center,United States) Shakira Pascual(,Memorial Sloan Kettering Cancer Center,United States) Anmol Shah(,Memorial Sloan Kettering Cancer Center,United States) Michael Silvestrone(Clinical Research Administration,Memorial Sloan Kettering Cancer Center,United States) Kenton Wu(,Memorial Sloan Kettering Cancer Center,United States) Hannah Levavi(,Icahn School of Medicine at Mount Sinai,United States) Tina Czaplinska(,Icahn School of Medicine at Mount Sinai,United States) Kathryn Johnson(,Ichan School of Medicine at Mount Sinai,United States) Meghan Thompson(,Memorial Sloan Kettering Cancer Center,United States) Eytan Stein(Leukemia Service, Department of Medicine,Memorial Sloan Kettering Cancer Center,United States) Yanming Zhang(Pathology,Memorial Sloan Kettering Cancer Center,United States) Andriy Derkach(,Memorial Sloan-Kettering Cancer Center,United States) Jae Park(Leukemia Service,Memorial Sloan-Kettering Cancer Center,United States)

Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory AcuteLymphoblastic Leukemia

Luskin M, et al.
Blood
September 2026
Authors and Affiliates
Marlise Luskin (Dana-Farber Cancer Institute, United States) Julia Keating (Dana-Farber Cancer Institute, United States) Benjamin Frost (Brigham and Women's Hospital, United States) Stella Jaeckle (Dana-Farber Cancer Institute, United States) Shai Shimony (Dana-Farber Cancer Institute, United States) Yael Flamand (Dana-Farber Cancer Institute, United States) Jacqueline Garcia (Dana Farber Cancer Institute, United States) Richard Stone (Dana-Farber Cancer Institute, United States) Matthew Booker (Dana-Farber Cancer Institute, United States) Chase Weizer (Dana-Farber Cancer Institute, United States) Jeremy Ryan (Dana-Farber Cancer Institute, United States) Jessica Lee (Dana-Farber Cancer Institute, United States) Ilene Galinsky (Dana Farber Cancer Institute, Harvard, United States) Sujal Shah (Brigham & Women's Hospital, United States) Emma Smith (Dana Farber Cancer Institute, United States) Arpita Kulkarni (Harvard Medical School, United States) Michael Tolstorukov (Dana-Farber Cancer Institute, United States) Evan Chen (Dana-Farber Cancer Institute, United States) Eric Winer (Dana-Farber Cancer Institute, United States) Anthony Letai (Dana-Farber Cancer Institute, United States) Mark Murakami (Dana-Farber Cancer Institute, United States) Daniel DeAngelo (Dana-Farber Cancer Institute, United States)

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma

Dekhtiarenko I, et al.
Blood Advances
September 2026
Authors and Affiliates
Iryna Dekhtiarenko (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Jan Attig (Roche Innovation Center Basel, pRED, Switzerland) Iva Lelios (Roche Innovation Center Basel, pRED, Switzerland) Stephan Schmeing (Roche Innovation Center Basel, pRED, Switzerland) Carmen Yong (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Wolfgang Jacob (Roche Innovation Center Munich, pRED, Germany) Emilio Yángüez (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Tamara Hüsser (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Llucia Albertí Servera (Roche Innovation Center Basel, pRED, Switzerland) Inga Clausen (Roche Innovation Center Basel, pRED, Switzerland) Hans Grote (Roche Innovation Center Munich, pRED, Germany) Cláudia Ferreira (Roche Innovation Center Munich, pRED, Switzerland) Hans-Joachim Helms (Roche Innovation Center Basel, pRED, Switzerland) Cristina Santini (Roche Innovation Center Basel, pRED, Switzerland) Emilie Schindler (Roche Innovation Center Basel, pRED, Switzerland) Sylvia Herter (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Marina Bacac (Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland) Carmelo Carlo-Stella (Humanitas University and IRCCS Humanitas Research Hospital, Italy) Anna Caroline Hasselbalch (Rigshospitalet, Denmark) Salomon Manier (CHU de Lille, France) Antonio Pinto (Istituto Nazionale dei Tumori "Fondazione G Pascale", IRCCS, Italy) Paolo Corradini (IRCCS Istituto Nazionale dei Tumori, University of Milano, Italy) Cyrille Hulin (CHU de Bordeaux, France) Sung-Soo Yoon (Seoul National University College of Medicine, Korea, Republic of) Rakesh Popat (NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, United Kingdom) Simon Harrison (Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Australia) Martin Weisser (Roche Innovation Center Munich, pRED, Germany) Ann- Marie Bröske (Roche Innovation Center Munich, pRED, Germany)

Teclistamab versus lenalidomide dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Nadeem O, et al.
Nature Communications
September 2026
Authors and Affiliates
Omar Nadeem 1,2,7, David M. Cordas dos Santos 1,2,7, Sophie Magidson1,2, Jeffrey Matous3, Eva Medvedova4, Elizabeth O’Donnell1,2, Robert A. Redd5, Yuxin Liu1,2, Shonali Midha 1,2, Adam S. Sperling 6, Frances Arters1,2, Christine Davie1,2, Caroline Ricciardi1,2, Rosa Toenges1,2, Nayda Bidikian1,2, Subear Hussein1,2, Jean-Baptiste Alberge1,2, Sungjae Kim1,2, Lorena Pantano-Rubino1,2, Francesco Corrado1,2, Hannah Ashton1,2, Daniel Addonizio1,2, Siham Mohamed1,2, Ashlee Sturtevant1,2, Marjorie Marto1,2, Amy Bergeron1,2, Francesco Malfona2, Kevin Panaro 2, Paul G. Richardson2, Jerome Ritz 2, Lorenzo Trippa 5 & Irene M. Ghobrial 1,2 1Center for Early Detection and Interception of Blood Cancers, Dana–Farber Cancer Institute, Boston, MA, USA. 2Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA, USA. 3Colorado Blood Cancer Institute, Denver, CO, USA. 4Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. 5Department of Data Science, Dana–Farber Cancer Institute, Boston, MA, USA. 6Division of Hematology, Stanford University, Palo Alto, CA, USA. 7These authors contributed equally: Omar Nadeem, David M. Cordas dos Santos.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractoryB-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 resultsfrom a single-arm, multicentre, phase 1/2 study

Kersten M, et al.
Lancet Haematology
September 2026
Authors and Affiliates
Marie José Kersten 1, Maria T Kuipers 2, Pim G N J Mutsaers 3, Evelyne Willems 4, Kirsten Saevels 5, Martin Dreyling 6, Caron Jacobson 7, Michael R Bishop 8, Maarten Zandvliet 9, Stavros Milatos 10, Chiara Lobetti-Bodoni 10, Sandra Blum 10, Kirsten Van Hoorde 11, Jigar Desai 12, Lorenzo Acciarri 13, Margot J Pont 9, Anna van Muyden 9, Omotayo Fasan 12, Joost S P Vermaat 14, Sébastien Anguille 5 1Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: m.j.kersten@amsterdamumc.nl. 2Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. 3Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4Department of Hematology, Centre Hospitalier Universitaire de Liège, Liège, Belgium. 5Division of Hematology and Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium. 6Department of Medicine III, LMU Hospital Munich, Munich, Germany. 7Division of Lymphoma, Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA. 8The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA. 9Galapagos, Leiden, Netherlands; CellPoint, Leiden, Netherlands. 10Galapagos, Basel, Switzerland. 11Open Analytics, Antwerp, Belgium. 12Galapagos, Princeton, NJ, USA. 13Valos, Genoa, Italy. 14Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial

Falchi L, et al.
Lancet Haematology
September 2026
Authors and Affiliates
Lorenzo Falchi 1, Joost S P Vermaat 2, Joshua D Brody 3, Lori Leslie 4, Fritz Offner 5, Jacob Haaber Christensen 6, Marcel Nijland 7, David Belada 8, Björn Engelbrekt Wahlin 9, Kristina Drott 10, Pilar Gomez Prieto 11, Kateřina Kopečkova 12, Alejandro Martín García-Sancho 13, Jian P Mei 14, Işıl Altıntaş 15, Malene Risum 16, Aidan Reilly 17, Jun Zou 17, Pau Abrisqueta 18 1Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: falchil@mskcc.org. 2Leiden University Medical Center, Leiden, Netherlands. 3Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA. 5Universitair Ziekenhuis Gent, Ghent, Belgium. 6Odense University Hospital, Odense, Denmark. 7University Medical Center Groningen and University of Groningen, Groningen, Netherlands. 8Hospital and Faculty of Medicine, Charles University, Hradec Králové, Czech Republic. 9Karolinska Institutet, Stockholm, Sweden. 10Skåne University Hospital, Lund, Sweden. 11Hospital Universitario La Paz, Madrid, Spain. 12Motol University Hospital, Charles University, Prague, Czech Republic. 13Hospital Universitario de Salamanca, IBSAL, CIBERONC, University of Salamanca, Salamanca, Spain. 14AbbVie, North Chicago, IL, USA. 15Genmab, Utrecht, Netherlands. 16Genmab, Copenhagen, Denmark. 17Genmab, Plainsboro, NJ, USA. 18Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes

Gould P, et al.
Haematologica
August 2026
Authors and Affiliates
*Patrick Gould,1,2 *Devyn Coskey,1 Xin Ma,1 Shikun Wang,1 Sonia Godbole,3 David Bond,3 Andrew Ip,4 Snegha Ananth,5 Shaunak Varma,6 Emily Ayers,6 Rachel Faden,7 Cassandra Gillespie,7 Basem William,7 Ryan Jacobs,8 Bei Hu,8 Jake Lattin,9 David Russler-Germain,9 Michele Stanchina,10 Ashley Rose,10 Michael Randall,11 Michael Spinner,11 Vidiya Srikakulapu,12 Praveen Ramakrishnan Geethakumari,12 Alan Skarbnik,13 David W. Chitty,14 Mazie Tsang,15 Cassandra Duarte,16 Ajay Major,16 Allison M. Bock,17 Kelsey Baron,17 Brian Hess,18 Seda Tolu,1 Barbara Pro,1 Supriya Vaidya,1 Jennifer E. Amengual,1 Ran Reshef,1 Hua-Jay J. Cherng1# 1Columbia University Irving Medical Center, New York, NY; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Ohio State University, Columbus, OH; 4Hackensack University Medical Center, Hackensack, NJ; 5University of Nebraska, Omaha, NE; 6University of Virginia, Charlottesville, VA; 7OhioHealth, Columbus, OH; 8Levine Cancer Institute, Atrium Health Wake Forest, Charlotte, NC; 9Washington University in St. Louis, St. Louis, MO; 10University of Miami, Miami, FL; 11University of California San Francisco, San Francisco, CA; 12University of Texas, Southwestern, Dallas, TX; 13Novant Health Cancer Institute, Charlotte, NC; 14Northwell Health, Lake Success, NY; 15Mayo Clinic Arizona, Phoenix, AZ; 16University of Colorado, Aurora, CO; 17University of Utah, Salt Lake City, UT; 18Medical University of South Carolina, Charleston, SC *P. G. and D. C contributed equally to this study
Previous Next